HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer
Chinese firms HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
Acotec Scientific’s AcoArt Camellia Receives NMPA Approval for Coronary Artery Disease Treatment
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...
REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia
Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San...
AccurEdit Therapeutics’ ART001 Shows Over 90% TTR Reduction in ATTR Amyloidosis Trial
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced positive results from an ongoing investigator-initiated trial...
Sanofi Announces EUR 1 Billion Investment for New Beijing Manufacturing Plant
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced plans to invest EUR 1 billion (USD...
Huadong Medicine’s SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis
Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA)...
Jiangsu Hengrui Pharmaceuticals’ Fluzoparib and Apatinib Gain NMPA Approval for Metastatic Breast Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Fangzhou Inc. Expands Partnerships with Tencent Healthcare and Baidu Health at Digital Summit
China-based Fangzhou Inc. (HKG: 6086) hosted the “Data and AI: Decoding Digital Engagement” summit in...
MGI Tech Co., Ltd Partners with Universidad de San Martín de Porre for Genomic Sequencing Advancement
China-based gene sequencing specialist MGI Tech Co., Ltd has announced a collaboration with the Universidad...
VFLO Medical Partners with Inari Medical to Expand Access in Greater China
China-based VFLO Medical, a peripheral vascular device firm incubated by 6 Dimensions Capital, has announced...
Uni-Bio Science Group Achieves Milestones in Medical Aesthetics with New Product Approvals
China-based Uni-Bio Science Group Limited (HKG: 0690) has announced two significant achievements in the medical...
Ocumen Therapeutics’ OT-301 Phase III Denali Study Surpasses 140 Patient Enrollment in China
Chinese ophthalmology specialist Ocumen Therapeutics (HKG: 1477) has announced the enrollment of more than 140...
China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics’ Gout Drug ABP-671
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with compatriot...
Novartis Secures Global Rights to PTC Therapeutics’ Huntington’s Disease Treatment PTC518
Swiss pharmaceutical giant Novartis (NYSE: NVS) has entered into a global license and collaboration agreement...
UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...
Minghui Pharmaceutical’s MH004 Ointment Meets Primary Endpoints in Atopic Dermatitis Phase III Study
Shanghai-based Minghui Pharmaceutical, a late-stage biopharmaceutical company specializing in immunology and oncology, has announced positive...
China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector
The National Health Commission (NHC) has released the “Pilot Work Plan for Expanding the Wholly...
Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US
China-based Hua Medicine (HKG: 2552) has announced the successful completion of a Phase Ia study...
Shanghai MicuRx’s MRX-4/Contezolid Meets Primary Endpoint in Phase III cSSTI Study
Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) has announced that its Phase III study for...
CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million
Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company...